Aclarubicin hydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100012

CAS#: 75443-99-1 (HCl)

Description: Aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.

Chemical Structure

img
Aclarubicin hydrochloride
CAS# 75443-99-1 (HCl)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 100012
Name: Aclarubicin hydrochloride
CAS#: 75443-99-1 (HCl)
Chemical Formula: C42H54ClNO15
Exact Mass: 847.32
Molecular Weight: 848.340
Elemental Analysis: C, 59.46; H, 6.42; Cl, 4.18; N, 1.65; O, 28.29

Price and Availability

Size Price Availability Quantity
50mg USD 3950 2 Weeks
Bulk inquiry

Related CAS #: 75443-99-1 (HCl); 57576-44-0 (free base).  

Synonym: Aclacinomycin; Aclacinomycin A hydrochloride; Aclarubicin Hydrochloride; Antibiotic MA144A1. Aclacin; Aclacinomycine; Aclacinon; Aclaplastin; Jaclacin. ACM; ACMA. MA144A1

IUPAC/Chemical Name: (1R,2R,4S)-methyl 4-(((2R,5S,6S)-4-(dimethylamino)-5-(((2S,4S,5S,6S)-4-hydroxy-6-methyl-5-(((2R,6S)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate hydrochloride

InChi Key: KUSMIBXCRZTVML-ZRMZNYNWSA-N

InChi Code: InChI=1S/C42H53NO15.ClH/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29;/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3;1H/t18-,19-,20-,24?,27-,28-,29-,30-,31-,35-,39+,40+,42+;/m0./s1

SMILES Code: O=C([C@H]1[C@@](O)(CC)C[C@H](O[C@H]2CC(N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC([C@H](C)O4)=O)[C@H](C)O3)[C@H](C)O2)C5=C(O)C6=C(C(C7=CC=CC(O)=C7C6=O)=O)C=C15)OC.[H]Cl

Appearance: Red solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:        

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Aclacinomycin A hydrochloride (Aclarubicin hydrochloride) shows discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome. Aclacinomycin A hydrochloride is also a dual inhibitor of topoisomerase I and II.
In vitro activity: ACR-induced apoptosis was assessed by caspase-3/7 activity. The caspase-3/7 activity after 6-h ACR treatment was remarkably increased at 0.2 and 0.5 μM in HL-60 cells (0.2 μM, p<0.01; 0.5 μM, p<0.001), and at 0.5 μM in HP100 cells (p<0.001). Caspase-3/7 in HL-60 cells had significant higher activity than that in HP100 cells at 0.2 and 0.5 μM (Figure 2B) (0.2 μM, p<0.001; 0.5 μM, p<0.05). These events were in good agreement with DNA ladder formation induced by ACR. Reference: Anticancer Res. 2019 Jul;39(7):3443-3451. https://pubmed.ncbi.nlm.nih.gov/31262868/
In vivo activity: TBD

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 125.0 147.35

Preparing Stock Solutions

The following data is based on the product molecular weight 848.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Mizutani H, Hayashi Y, Hashimoto M, Imai M, Ichimaru Y, Kitamura Y, Ikemura K, Miyazawa D, Ohta K, Ikeda Y, Maeda T, Yoshikawa M, Hiraku Y, Kawanishi S. Oxidative DNA Damage and Apoptosis Induced by Aclarubicin, an Anthracycline: Role of Hydrogen Peroxide and Copper. Anticancer Res. 2019 Jul;39(7):3443-3451. doi: 10.21873/anticanres.13490. PMID: 31262868. 2. Gajek A, Rogalska A, Koceva-Chyła A. Aclarubicin in subtoxic doses reduces doxorubicin cytotoxicity in human non-small cell lung adenocarcinoma (A549) and human hepatocellular carcinoma (HepG2) cells by decreasing DNA damage. Toxicol In Vitro. 2019 Mar;55:140-150. doi: 10.1016/j.tiv.2018.12.015. Epub 2018 Dec 20. PMID: 30579959.
In vitro protocol: 1. Mizutani H, Hayashi Y, Hashimoto M, Imai M, Ichimaru Y, Kitamura Y, Ikemura K, Miyazawa D, Ohta K, Ikeda Y, Maeda T, Yoshikawa M, Hiraku Y, Kawanishi S. Oxidative DNA Damage and Apoptosis Induced by Aclarubicin, an Anthracycline: Role of Hydrogen Peroxide and Copper. Anticancer Res. 2019 Jul;39(7):3443-3451. doi: 10.21873/anticanres.13490. PMID: 31262868. 2. Gajek A, Rogalska A, Koceva-Chyła A. Aclarubicin in subtoxic doses reduces doxorubicin cytotoxicity in human non-small cell lung adenocarcinoma (A549) and human hepatocellular carcinoma (HepG2) cells by decreasing DNA damage. Toxicol In Vitro. 2019 Mar;55:140-150. doi: 10.1016/j.tiv.2018.12.015. Epub 2018 Dec 20. PMID: 30579959.
In vivo protocol: TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Dou L, Xu Q, Wang M, Xiao Y, Cheng L, Li H, Huang W, Mei J, Jing Y, Bo J, Liu D, Yu L. Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia. Onco Targets Ther. 2019 Jun 28;12:5013-5023. doi: 10.2147/OTT.S200005. PMID: 31303761; PMCID: PMC6605041.


2: Kawashima O, Kurihara T, Kamiyoshihara M, Sakata S, Ishikawa S, Morishita Y. Management of malignant pericardial effusion resulting from recurrent cancer with local instillation of aclarubicin hydrochloride. Am J Clin Oncol. 1999 Aug;22(4):396-8. doi: 10.1097/00000421-199908000-00015. PMID: 10440198.


3: Ichihara T, Sakamoto K, Mori K, Akagi M. Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride. Cancer Res. 1989 Aug 1;49(15):4357-62. PMID: 2472878.


4: Tsuda T, Okamoto Y, Sakaguchi R, Katayama N, Ota K. The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study. J Int Med Res. 2001 Jan-Feb;29(1):41-7. doi: 10.1177/147323000102900107. PMID: 11277347.


5: Mori S, Ogasawara T, Nishimura M, Miura H, Goto S, Oki T, Inui T. Physiochemical properties and stability of aclacinomycin A hydrochloride. Jpn J Antibiot. 1980 May;33(5):618-22. PMID: 6933235.


6: Xu Q, Li Y, Jing Y, Lv N, Wang L, Li Y, Yu L. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen. Int J Cancer. 2020 Mar 1;146(5):1457-1467. doi: 10.1002/ijc.32593. Epub 2019 Aug 14. PMID: 31344264.


7: Wada R, Hyon SH, Ikada Y. Lactic acid oligomer microspheres containing hydrophilic drugs. J Pharm Sci. 1990 Oct;79(10):919-24. doi: 10.1002/jps.2600791016. PMID: 2280363.


8: Tanaka T, Kobayashi T, Kida Y. [Combined chemotherapy with cisplatin and aclarubicin hydrochloride for metastatic brain tumors]. No Shinkei Geka. 1988 Jan;16(1):23-8. Japanese. PMID: 3163105.


9: Poochikian GK, Cradock JC, Flora KP. Stability of anthracycline antitumor agents in four infusion fluids. Am J Hosp Pharm. 1981 Apr;38(4):483-6. PMID: 6945043.


10: Ma Y, Shen J, Wang LX. Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review. Medicine (Baltimore). 2018 Apr;97(16):e0434. doi: 10.1097/MD.0000000000010434. PMID: 29668607; PMCID: PMC5916686.


11: Mori S, Shindo N, Miura H, Oki T, Inui T. [Studies on the stability of aclacinomycin hydrochloride. I. Stability of solution of aclacinomycin hydrochloride (author's transl)]. Jpn J Antibiot. 1980 Apr;33(4):466-71. Japanese. PMID: 7411850.


12: Matsuno S, Hisano H, Kobari M, Akaishi S. Growth-inhibitory effect of combination chemotherapy for human pancreatic cancer cell lines. Cancer. 1990 Dec 1;66(11):2369-74. doi: 10.1002/1097-0142(19901201)66:11<2369::aid- cncr2820661120>3.0.co;2-z. PMID: 2123126.


13: Ninomiya H, Nakazawa M, Shibuya A, Aoki Y, Nagasawa T, Abe T. Successful treatment of acute megakaryoblastic leukaemia. Scand J Haematol. 1986 Feb;36(2):147-53. doi: 10.1111/j.1600-0609.1986.tb00819.x. PMID: 3458290.


14: Ueda K, Jinno H, Watanabe H, Ohtaguro K. [Combination effects of CDDP, ACR and HCFU on progressive urothelial tumors]. Gan To Kagaku Ryoho. 1985 Jun;12(6):1318-22. Japanese. PMID: 3859251.